The Global Antisense Oligonucleotide Therapeutics Market is estimated to reach over USD 64.46 billion by 2030, exhibiting a CAGR of 12.90% during the forecast period.
Antisense oligonucleotide is crucial in present medicine because it inhibits the expression of disease-causing genes by acting on messenger RNA before the protein is produced. This is attributed to rising antisense drug acceptability, increased R&D funding, rising neurodegenerative disorders, and an ageing population. The antisense oligonucleotides market will benefit from a high number of regulatory approvals from the Food and Drug Administration (FDA), for the use of innovative antisense oligonucleotides medications. Furthermore, mergers and acquisitions to enhance their product offerings are expected to be a major driver for the worldwide antisense oligonucleotides market over the upcoming years.
However, the high cost of antisense oligonucleotide therapeutics and the availability of synthetic chemicals are factors projected to limit the overall growth of the antisense oligonucleotide therapeutics market over the coming years. In addition, developing a new set of unique regulatory requirements is a difficulty that is inhibiting the worldwide antisense oligonucleotide market's growth. Also, Investments by prominent players are factors expected to create lucrative growth opportunities in terms of revenue for players operating in the global Antisense Oligonucleotide Therapeutics market over the forecast period.
The Antisense Oligonucleotide Therapeutics market is segmented based on Therapy, molecule target indication and target indication. Based on Therapy, the market is categorized into Monotherapy, Combination. Based on molecule target indication application, the market is segmented into DNA Molecule andrena Molecule. Based on target indication market is segmented into Duchenne Muscular Atrophy, Spinal Muscular Atrophy, Familial Chylomicronemia Syndrome, Amyotrophic Lateral Sclerosis, Familial Partial Lipodystrophy, Hereditary Transthyretin-Mediated (hatter) Amyloidosis, Huntington's Disease and Others.
Based on Therapy, the monotherapy segment is accounted as a major contributor in the Antisense Oligonucleotide Therapeutics market
The Monotherapy category is expected to hold a major share in the global Antisense Oligonucleotide Therapeutics market in 2021. The market is expected to increase due to a rise in regulatory approvals of monotherapy medications. Furthermore, the increased prevalence of prostate cancer is expected to drive the market forward during the forecast period.
RNA Molecule segment witnessed growth at a rapid rate
The RNA Molecule segment is projected to grow at a rapid rate in the global Antisense Oligonucleotide Therapeutics market during the forecast period. Collaboration operations between pharmaceutical firms and Contract Research Organizations (CROs) focusing on drug delivery are projected to benefit the antisense & RNA molecule industry, particularly in nations such as the United States, Germany, the United Kingdom, China, and India. In addition, many other antisense technologies and oligonucleotide molecules are also being developed for non-neurodegenerative disorders.
In the region, the North America Antisense Oligonucleotide Therapeutics market holds a significant revenue share.
The North America Antisense Oligonucleotide Therapeutics market is expected to register the highest market share in terms of revenue soon. Several biotechnology companies have made significant expenditures on the development of RNAi therapeutics. Big pharmaceutical companies have gone into partnership or license arrangements with several smaller companies to profit from the predicted revenue increase in this industry over the projection period. Several medication candidates now undergoing clinical trials have shown promising results and are moving forward in the development process. If such studies continue to yield positive results, the North American market is likely to see a significant demand increase throughout the forecast period.
Europe is expected to be the dominant region in the global antisense oligonucleotides market over the forecast period. This is due to the region's rising approval of novel antisense oligonucleotide medications. In addition to enhancing their product offers in antisense oligonucleotides, key companies in Europe are focusing on strategic mergers and acquisitions.
The key players in the Antisense Oligonucleotide Therapeutics market have shifted their focus towards bio-based components for product manufacturing and are initiating effective strategies such as mergers, acquisitions, and joint ventures of major and domestic players to enhance product portfolio and strengthen their market footprint across the globe. Some of the major key players in the Antisense Oligonucleotide Therapeutics market are Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Sarna Therapeutics GmbH, Arrowhead Pharmaceuticals, Inc., Atlantic Pharmaceuticals, Inc., Enzo Pharmaceuticals, Inc., Bio-Path Holdings, Inc., Gene Signal International SA, GlaxoSmithKline plc, Gerona Corporation, Gradualist, ICO Therapeutics, Aptos Biosciences, Marina Biotech, mirage Therapeutics, Inc., Synodic, Inc., Oncogene Pharmaceuticals Inc., Pharm axis Ltd, Regulus Therapeutics Inc., Reran Pharmaceuticals, Inc., and RI Pharmaceuticals, among others.